RESUMO
Importance: The prompt effective treatment of acute agitation among patients with schizophrenia or bipolar disorder can alleviate distressing symptoms for the patient and decrease the risk of escalation to aggression and the potential for serious harm to the patient, health care providers, and others.Observations: A commonly used approach for the management of acute agitation has been the intramuscular administration of antipsychotic medications and/or benzodiazepines. However, US Food and Drug Administration-approved treatments with alternative routes of delivery now include inhaled loxapine powder and, more recently, dexmedetomidine sublingual film. Two formulations of intranasal olanzapine for acute agitation are in development.Conclusions and Relevance: Intranasal formulations offer the potential for favorable pharmacokinetics and onset of action combined with ease of delivery obviating the need for injections and are thus consistent with patient-centered factors such as preference and self-administration. In this review, alternative methods of medication delivery are discussed, with an emphasis on the potential for intranasal administration to treat acute agitation in adult patients with schizophrenia or bipolar disorder.Prim Care Companion CNS Disord 2024;26(1):23nr03596. Author affiliations are listed at the end of this article.
Assuntos
Antipsicóticos , Transtorno Bipolar , Loxapina , Esquizofrenia , Adulto , Humanos , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológico , Antipsicóticos/uso terapêutico , Transtorno Bipolar/complicações , Transtorno Bipolar/tratamento farmacológico , Agitação Psicomotora/tratamento farmacológico , Agitação Psicomotora/etiologia , Loxapina/efeitos adversosRESUMO
Objective: To assess the efficacy and safety of loxapine in acute agitation.Data Sources: PubMed, Cochrane database, EMBASE, PsycINFO, and ClinicalTrials.gov were searched to identify relevant articles published in English or French from inception to March 15, 2022. The term "Loxap*" was searched in titles and abstracts.Study Selection and Data Extraction: Interventional studies that compared the effectiveness of loxapine to any other intervention (including another administration route or dosage of loxapine, other drugs, and placebo) in acute agitation were included. From the 1,435 articles initially identified, and after the assessment of 73 full texts, 7 articles were selected, encompassing 1,276 participants. Two reviewers independently extracted data of interest using a predefined form.Results: Among included studies, 5 were double-blind, 2 were open-label, and all were randomized. The risk of bias was low for 2 studies, involving 658 participants. Four articles compared loxapine to placebo, and 3 compared it with haloperidol, aripiprazole, and droperidol. Loxapine was found to be more effective and faster regarding acute agitation control. Also, across included studies, loxapine was well-tolerated, with mildly or moderately severe adverse effects.Conclusions: Notwithstanding methodological limitations of the included studies, this systematic review provides reassuring results regarding the use of loxapine in acute agitation. However, further studies with methodological optimizations might be of interest.Prim Care Companion CNS Disord 2023;25(6):23r03552. Author affiliations are listed at the end of this article.
Assuntos
Antipsicóticos , Loxapina , Humanos , Loxapina/efeitos adversos , Antipsicóticos/efeitos adversos , Administração por Inalação , Agitação Psicomotora/tratamento farmacológico , Aripiprazol/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como AssuntoAssuntos
Antipsicóticos/efeitos adversos , Loxapina/efeitos adversos , Atividade Motora/efeitos dos fármacos , Agitação Psicomotora/tratamento farmacológico , Adulto , Humanos , Masculino , Pessoa de Meia-Idade , Agitação Psicomotora/diagnóstico , Agitação Psicomotora/fisiopatologia , Agitação Psicomotora/psicologia , Indução de Remissão , Resultado do TratamentoAssuntos
Transtorno Bipolar/psicologia , Catatonia/psicologia , Síndrome Maligna Neuroléptica/psicologia , Adolescente , Antipsicóticos/efeitos adversos , Transtorno Bipolar/complicações , Catatonia/complicações , Eletroencefalografia , Humanos , Hipnóticos e Sedativos/uso terapêutico , Lorazepam/uso terapêutico , Loxapina/efeitos adversos , Masculino , Síndrome Maligna Neuroléptica/complicaçõesAssuntos
Acatisia Induzida por Medicamentos/etiologia , Antipsicóticos/efeitos adversos , Aripiprazol/efeitos adversos , Distonia/induzido quimicamente , Loxapina/efeitos adversos , Transtornos Psicóticos/tratamento farmacológico , Adolescente , Transtorno do Espectro Autista/psicologia , Delusões/complicações , Delusões/tratamento farmacológico , Delusões/psicologia , Feminino , Alucinações/tratamento farmacológico , Alucinações/psicologia , Humanos , Hipnóticos e Sedativos/uso terapêutico , Deficiência Intelectual/psicologia , Lorazepam/uso terapêutico , Olanzapina/uso terapêutico , Transtornos Paranoides/tratamento farmacológico , Transtornos Paranoides/psicologia , Transtornos Psicóticos/psicologia , Fumarato de Quetiapina/uso terapêutico , Síndrome de Tourette/psicologiaRESUMO
Inhaled Loxapine (IL) has demonstrated efficacy in the treatment of agitation in schizophrenic and bipolar patients, although data in patients with Personality Disorder (PD) are scarce. To evaluate the effectiveness and safety of IL in the treatment of agitation in PD, data from 41 patients who presented at our unit with acute agitation and were treated with 9.1â¯mg of IL were collected retrospectively. The results showed that IL significantly decreased agitation within 10 minutes and its effect was greater at 20 minutes (Positive and Negative Syndrome Scale-excited component: from 22.78⯱â¯4.39 at baseline to 11.14⯱â¯4.17 at 20 minutes; pâ¯<â¯0.001; Agitation and Calmness Evaluation Scale: from 1.80⯱â¯0.49 at baseline to 4.53⯱â¯1.05 at 20 minutes; pâ¯<â¯0.01) without any severe adverse reactions registered. IL led to fast, safe and well-tolerated control of agitation in patients with PD.
Assuntos
Loxapina/uso terapêutico , Transtornos da Personalidade/tratamento farmacológico , Agitação Psicomotora/tratamento farmacológico , Administração por Inalação , Adolescente , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Bases de Dados Factuais , Feminino , Humanos , Loxapina/administração & dosagem , Loxapina/efeitos adversos , Masculino , Pessoa de Meia-Idade , Transtornos da Personalidade/complicações , Agitação Psicomotora/complicações , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided rapid control of mild to moderate agitation in the hospital setting. The present study was designed to investigate the safety and efficacy of inhaled loxapine when self-administered outside the hospital setting. METHODS AND ANALYSIS: This phase IV, multicentre, single-arm, open-label clinical trial is being conducted in five countries in Europe: Spain, Germany, Norway, Romania and Austria. The aim is to include approximately 500 patients with schizophrenia or bipolar disorder who previously received and responded well to inhaled loxapine in the hospital setting. Eligible patients will be followed up for 6 months from baseline. They will be given a 10 mg dose of inhaled loxapine to self-administer outside the hospital setting to treat an agitation episode, should one occur. Patients will also be given a short-acting beta-agonist bronchodilator for treatment of possible severe respiratory side effects. The primary endpoint is incidence of serious adverse events (AEs) and respiratory AEs of special interest related to use of inhaled loxapine outside the hospital setting. Secondary endpoints include incidence of other AEs, Clinical Global Impression-Improvement scores up to 2 hours after self-administration of inhaled loxapine, time to improvement of agitation, patient satisfaction with treatment, treatment outcomes according to agitation severity and concordance between the patient (or a family member/caregiver) and the physician in scoring of agitation severity and the decision to self-administer inhaled loxapine. ETHICS AND DISSEMINATION: The protocol received ethics committee approval in the participating countries between January and August 2016. The results of this study will be disseminated through one or more scientific papers. TRIAL REGISTRATION NUMBER: EudraCT2015-003331-36; NCT02525991; Pre-results.
Assuntos
Antipsicóticos/administração & dosagem , Transtorno Bipolar/complicações , Loxapina/administração & dosagem , Agitação Psicomotora/tratamento farmacológico , Esquizofrenia/complicações , Administração por Inalação , Antipsicóticos/efeitos adversos , Ensaios Clínicos Fase IV como Assunto , Europa (Continente) , Humanos , Loxapina/efeitos adversos , Estudos Multicêntricos como Assunto , Nebulizadores e Vaporizadores , Autoadministração , Resultado do TratamentoRESUMO
We report the success of tardive electroconvulsive therapy in a case of loxapine malignant syndrome with catatonia. Loxapine and its metabolites were measured in biological samples by liquid chromatography coupled to tandem mass spectrometry. Genes were studied by sequencing and quantitative polymerase chain reaction (PCR). Plasmatic drug concentrations showed a supratherapeutic concentration of loxapine with a very low 8-hydroxyloxapine/loxapine ratio (range from 0.32 to 0.66, normal value>2 for 100mg) and a very long elimination half-life of loxapine (half-life>140h, normal value from 1 to 4hours). We tried to explain this kinetics by exploring the main pharmacogenes implicated in the metabolism of loxapine. No genetic abnormality for CYP1A2 was observed. The study of associated treatments showed the potential contribution of valproate. Pharmacokinetics and pharmacogenetics investigations revealed a blockade of the CYP1A2 metabolic pathway without genetic abnormalities, probably due to valproate co-medication. Toxicological monitoring of loxapine and its metabolites helped to explain the persistence of symptoms and to adapt the therapeutic management.
Assuntos
Antipsicóticos/efeitos adversos , Eletroconvulsoterapia/métodos , Loxapina/efeitos adversos , Síndrome Maligna Neuroléptica/terapia , Antipsicóticos/administração & dosagem , Antipsicóticos/farmacocinética , Cromatografia Líquida/métodos , Citocromo P-450 CYP1A2/genética , Feminino , Meia-Vida , Humanos , Loxapina/administração & dosagem , Loxapina/farmacocinética , Pessoa de Meia-Idade , Síndrome Maligna Neuroléptica/etiologia , Farmacogenética , Reação em Cadeia da Polimerase , Espectrometria de Massas em Tandem/métodos , Resultado do TratamentoRESUMO
WHAT IS KNOWN AND OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a rare but severe adverse effect of antipsychotic drugs. CASE DESCRIPTION: We report two cases of NMS highlighted by clinical pharmacists in an emergency unit during summer. One of them was fatal. Medication reconciliation processes performed at admission identified treatment with loxapine for one of them and with loxapine and clozapine for the other. Interview of the patients highlighted clinical symptoms suggesting NMS, allowing the pharmacists to alert the medical team. WHAT IS NEW AND CONCLUSION: Adverse drug events may be severe and clinical pharmacists in emergency departments can help to detect them.
Assuntos
Antipsicóticos/efeitos adversos , Síndrome Maligna Neuroléptica/diagnóstico , Farmacêuticos/organização & administração , Idoso , Antipsicóticos/administração & dosagem , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Serviço Hospitalar de Emergência/organização & administração , Evolução Fatal , Humanos , Loxapina/administração & dosagem , Loxapina/efeitos adversos , Masculino , Pessoa de Meia-Idade , Síndrome Maligna Neuroléptica/etiologia , Serviço de Farmácia Hospitalar/organização & administração , Papel ProfissionalRESUMO
This multisite open-label study sought to characterize the pharmacokinetics and safety of a single dose of inhaled loxapine in children and adolescents. Loxapine powder for oral inhalation was administered via a single-use handheld drug device to children and adolescents (aged 10-17 years) with any condition warranting chronic antipsychotic use. Patients were dosed according to body weight and cohort (<50 kg [n = 15], 2.5 or 5 mg; ≥50 kg [n = 15], 5 or 10 mg); the first 6 patients (cohort 1) enrolled in each weight group received the lower dose. Patients were enrolled in the higher-dose group (cohort 2) after an interim pharmacokinetic and safety analysis of data from cohort 1. Blood samples were collected for 48 hours after dosing to determine the pharmacokinetic profile of loxapine and its metabolites. Safety was assessed using adverse event (AE), laboratory value, physical/neurologic examination, vital sign, electrocardiogram, suicidality, and extrapyramidal symptom assessment. Thirty patients were enrolled and evaluable for pharmacokinetics. Loxapine plasma concentrations peaked by 2 to 5 minutes in most patients; systemic exposure increased with dose in both weight subgroups. Loxapine terminal elimination half-life was â¼13 to 17 hours. The most common AEs were sedation and dysgeusia. Sedation was severe in 1 patient in the <50-kg group (2.5-mg dose) and 1 patient in the ≥50-kg group (5-mg dose). No AEs indicative of bronchospasm or other serious AEs were reported. Inhaled loxapine was rapidly absorbed and generally well tolerated in pediatric patients; no new safety signals were observed.
Assuntos
Antipsicóticos/farmacocinética , Loxapina/farmacocinética , Administração por Inalação , Adolescente , Antipsicóticos/efeitos adversos , Antipsicóticos/sangue , Criança , Feminino , Humanos , Loxapina/efeitos adversos , Loxapina/sangue , MasculinoRESUMO
BACKGROUND: The management of acute agitation manifesting in patients with schizophrenia or bipolar disorder requires swift pharmacological intervention to provide rapid symptomatic relief and prevent escalation to aggression and violence. Antipsychotic medications are widely used in this setting and the availability of an inhaled formulation with deep lung absorption of the antipsychotic loxapine has the potential to deliver a faster onset of therapeutic effect than the available intramuscular formulations of antipsychotics. METHODS: The efficacy of inhaled loxapine and the alternative antipsychotic aripiprazole delivered via intramuscular (IM) injection will be compared in the Phase IIIb PLACID study. Adults (18-65 years) with a confirmed diagnosis of schizophrenia or bipolar I disorder presenting with acute agitation will be randomly assigned to open-label treatment in a 1:1 ratio. Clinical evaluation will be conducted by raters blinded to treatment assignment. The primary efficacy endpoint is time to response (defined as a Clinical Global Impression of Improvement [CGI-I] score of 1 [very much improved] or 2 [much improved]). Secondary endpoints will include the percentage of responders at different time points after dosing; the proportion of patients who receive 1 or 2 doses of study drug; time to second dose; time to rescue medication; satisfaction with study drug (evaluated using Item 14 of the Treatment Satisfaction Questionnaire for Medication); and safety and tolerability. Approximately 360 patients will be recruited with an interim analysis conducted once 180 patients have completed the study to decide whether to stop for futility or continue with or without an increase in the sample size up to additional 288 patients. DISCUSSION: The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder. In the event that the median time to response of inhaled loxapine is significantly shorter than that of the intramuscular aripiprazole, the PLACID study has the potential to support the inhaled antipsychotic therapy as the standard of care in this setting. TRIAL REGISTRATION: The study protocol was registered with the European Clinical Trials Database on the 31 October 2014 (EudraCT number 2014-000456-29 ).
Assuntos
Agressão/efeitos dos fármacos , Aripiprazol/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Protocolos Clínicos , Loxapina/uso terapêutico , Agitação Psicomotora/tratamento farmacológico , Psicologia do Esquizofrênico , Administração por Inalação , Adolescente , Adulto , Idoso , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Aripiprazol/administração & dosagem , Aripiprazol/efeitos adversos , Transtorno Bipolar/complicações , Humanos , Injeções Intramusculares , Loxapina/administração & dosagem , Loxapina/efeitos adversos , Masculino , Pessoa de Meia-Idade , Agitação Psicomotora/complicações , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológico , Resultado do Tratamento , Adulto JovemRESUMO
Loxapine is a first generation antipsychotic, belonging to the dibenzoxazepine class. Recently, loxapine has been reformulated at a lower dose, producing an inhaled powder that can be directly administered to the lungs to treat the agitation associated with psychiatric disorders, such as schizophrenia and bipolar disorder. Thus, the aim of this narrative and clinical mini-review was to evaluate the efficacy and tolerability of inhaled loxapine in the treatment of acute agitation in patients with psychiatric disorders. The efficacy of inhaled loxapine has been evaluated in one Phase II trial on patients with schizophrenia, and in two Phase III trials in patients with schizophrenia and bipolar disorder. Moreover, there are two published case series on patients with borderline personality disorder and dual diagnosis patients. Inhaled loxapine has proven to be effective and generally well tolerated when administered to agitated patients with schizophrenia and bipolar disorder. Two case series have suggested that inhaled loxapine may also be useful to treat agitation in patients with borderline personality disorder and with dual diagnosis, but further studies are needed to clarify this point. However, the administration of inhaled loxapine requires at least some kind of patient collaboration, and is not recommended in the treatment of severe agitation in totally uncooperative patients. Moreover, the drug-related risk of bronchospasm must always be kept in mind when planning to use inhaled loxapine, leading to a careful patient assessment prior to, and after, administration. Also, the higher costs of inhaled loxapine, when compared to oral and intramuscular medications, should be taken into account when selecting it for the treatment of agitation.
Assuntos
Antipsicóticos/administração & dosagem , Loxapina/administração & dosagem , Transtornos Mentais/complicações , Agitação Psicomotora/tratamento farmacológico , Agitação Psicomotora/etiologia , Antipsicóticos/efeitos adversos , Antipsicóticos/farmacocinética , Ensaios Clínicos como Assunto , Humanos , Inalação , Loxapina/efeitos adversos , Loxapina/farmacocinética , Transtornos Mentais/diagnóstico , Resultado do TratamentoAssuntos
Antipsicóticos/administração & dosagem , Ensaios Clínicos como Assunto/estatística & dados numéricos , Internet/estatística & dados numéricos , Loxapina/administração & dosagem , Administração por Inalação , Antipsicóticos/efeitos adversos , Ensaios Clínicos como Assunto/métodos , Humanos , Loxapina/efeitos adversos , Segurança do Paciente , Agitação Psicomotora/diagnóstico , Agitação Psicomotora/prevenção & controleRESUMO
BACKGROUND: Acute agitation is a serious complication of schizophrenia and bipolar disorder, which may escalate quickly to aggressive behavior. Rapid treatment is therefore important to calm and stabilize the patient, reducing the potential for harm to the patient and others, and allowing further assessment. Current guidelines suggest that where pharmacologic intervention is indicated, medication should preferably be non-invasive, should have a rapid onset and should control aggressive behavior in the short term without compromising the physician-patient relationship in the long term. OBJECTIVES: This article presents an overview of a new inhaled formulation of the established antipsychotic loxapine, which aims to provide a more rapidly acting agent for the treatment of acute agitation without the disadvantages of intramuscular or intravenous injection. DISCUSSION: Inhaled loxapine is rapidly absorbed with intravenous-like pharmacokinetics, with a time to maximum plasma concentration of 2 minutes and a plasma half-life of approximately 6 hours. In phase III studies, loxapine reduced agitation within 10 minutes of inhalation; agitation was decreased at all subsequent assessments during a 24-hour evaluation period. Inhaled loxapine was generally well tolerated with no undue sedation. The most common adverse events were dysgeusia, mild sedation, and dizziness. Inhaled loxapine is contraindicated in patients with asthma, COPD or other pulmonary disease associated with bronchospasm. CONCLUSIONS: Inhaled loxapine rapidly reduces acute agitation in patients with schizophrenia or bipolar disorder and is generally well tolerated. The non-invasive route of delivery respects the patient's autonomy, reducing the perception of coercion or forced medication. Inhaled loxapine is therefore an effective and appropriate option for use in the emergency setting in patients with acute agitation.
Assuntos
Antipsicóticos , Transtorno Bipolar/tratamento farmacológico , Loxapina , Agitação Psicomotora/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Administração por Inalação , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Humanos , Loxapina/administração & dosagem , Loxapina/efeitos adversos , Loxapina/farmacocinética , Loxapina/uso terapêuticoRESUMO
OBJECTIVE: New and repurposed drugs are urgently needed to treat individuals with autism spectrum disorders (ASD). Loxapine (LOX) in low doses of 5-15 mg/day resembles an atypical antipsychotic (Stahl 2002 ). Our recent open pilot study of LOX found significant behavioral improvements and overall weight neutrality in 16 adolescents and adults with ASD. The present study examined an outpatient sample for LOX neuromotor tolerability. METHODS: Consecutive outpatients with Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR) ASD diagnoses receiving LOX were examined for tardive dyskinesia (TD) and extrapyramidal side effects (EPS) using the Dyskinesia Identification System: Condensed User Scale (DISCUS), and for akathisia using the Barnes Akathisia Rating Scale. Data were also then retrospectively extracted from clinic charts regarding age, gender, diagnoses, LOX doses, treatment duration, concomitant medications, and LOX dosage reductions. RESULTS: Thirty-four subjects (25 male, 9 female) participated. Mean age was 23.4 years at LOX initiation (range 8-52). Thirteen subjects (38.2%) received loxapine for ≥5 years. Mean LOX dose was 8.9 mg/day (range 5-30 mg) and mean duration was 4.2 years (range 0.8-13). Fourteen subjects (41.2%) received concomitant atypical antipsychotics. Benztropine was prescribed in 5 of 34 subjects (14.7%). Three subjects manifested tics at baseline, but lower final DISCUS scores. Subject 26, with Prader-Willi syndrome, manifested TD. Apart from LOX 5 mg daily he received paroxetine 40 mg daily, which reduces LOX metabolism significantly. Akathisia objective scores were positive in 6 subjects (17.6%): Subject 2 scored 3 (pacing was present also at baseline); subjects 6, 7, and 11 each scored 1; and subjects 18 and 23 each scored 2. Six of 9 subjects (66.7%) with expressive language were positive for subjective akathisia. CONCLUSIONS: Low dose LOX was well tolerated, with lower than expected TD rates. This confirms clinical resemblance to an atypical antipsychotic. Individuals with neuromuscular problems including Prader-Willi Syndrome receiving LOX require close monitoring. Further study of LOX in ASD is warranted.
Assuntos
Acatisia Induzida por Medicamentos/epidemiologia , Transtorno do Espectro Autista/tratamento farmacológico , Discinesia Induzida por Medicamentos/epidemiologia , Loxapina/administração & dosagem , Loxapina/efeitos adversos , Adolescente , Adulto , Acatisia Induzida por Medicamentos/complicações , Transtorno do Espectro Autista/complicações , Criança , Estudos Transversais , Discinesia Induzida por Medicamentos/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Adulto JovemRESUMO
OBJECTIVE: This randomized, double-blind, active- and placebo-controlled, crossover, thorough QT study assessed the effect of two inhaled loxapine doses on cardiac repolarization as measured by corrected QT (QTc) interval in healthy subjects (ClinicalTrials.gov NCT01854710). METHODS: Subjects received two doses of inhaled loxapine (10 mg) 2 hours apart+oral placebo, two doses of inhaled placebo+oral placebo, or two doses of inhaled placebo+oral moxifloxacin (400 mg; positive control), with ≥3 days washout between treatments. Two-sided 90% confidence intervals (CIs) were calculated around least-squares mean predose placebo-subtracted individually corrected QT durations (ΔΔTcIs) at 12 time points throughout 24 hours after dosing. A ΔΔTcI 95% upper CI exceeding 10 msec was the threshold indicating QTc prolongation (primary endpoint). Secondary endpoints included Fridericia- and Bazett-corrected QT duration and QTcI outliers. Pharmacokinetics and adverse events (AEs) were also assessed. RESULTS: Of 60 subjects enrolled (mean age, 33.8 years; 52% male), 44 completed the study. Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2. Methodology was validated by ΔΔTcI 95% lower CIs exceeding 5 msec at 9 of 12 time points after moxifloxacin dosing. Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1). There were no deaths, serious AEs, or AEs leading to discontinuation, and one severe AE. CONCLUSIONS: Primary and secondary endpoints indicated two therapeutic doses of inhaled loxapine did not cause threshold QTc prolongation in this study.
Assuntos
Antipsicóticos/administração & dosagem , Sistema de Condução Cardíaco/efeitos dos fármacos , Loxapina/administração & dosagem , Potenciais de Ação , Administração por Inalação , Adulto , Antipsicóticos/efeitos adversos , Antipsicóticos/sangue , Antipsicóticos/farmacocinética , Biotransformação , Estudos Cross-Over , Método Duplo-Cego , Esquema de Medicação , Feminino , Voluntários Saudáveis , Sistema de Condução Cardíaco/fisiologia , Humanos , Análise dos Mínimos Quadrados , Loxapina/efeitos adversos , Loxapina/análogos & derivados , Loxapina/sangue , Loxapina/farmacocinética , Masculino , Pessoa de Meia-Idade , Medição de Risco , Resultado do Tratamento , Adulto JovemRESUMO
Atypical antipsychotics, the first line therapy for schizophrenia, have already been reported as causing rhabdomyolysis or isolated elevation in serum creatine kinase (SCK). This case report dealing with rhabdomyolysis in a 25-year-old man treated with antipsychotics is particularly unusual, due to the extremely high elevation in SCK and the ensuing acute renal failure. He was treated with loxapine 400 mg/day and risperidone 4 mg/day for 4 days and then loxapine was replaced by levomepromazine 300 mg/day. A series of laboratory examinations showed: SCK 43 650 UI/L, creatinine 392 µmol/L. An acute renal failure (acute tubular necrosis) after iatrogenic rhabdomyolysis was diagnosed, requiring hemodialysis. Furthermore, the patient also developed a deep vein thrombosis (DVT) attributed to his antipsychotic treatment. This case underlines the importance of taking rhabdomyolysis and DVT risk factors into account in patients treated with antipsychotics. Indeed, in this case we note that rhabdomyolysis was probably promoted by the interruption and the reintroduction of the treatment more than by possible dehydration, because no other risk factor could be identified.
Assuntos
Injúria Renal Aguda/induzido quimicamente , Antipsicóticos/efeitos adversos , Loxapina/efeitos adversos , Rabdomiólise/induzido quimicamente , Risperidona/efeitos adversos , Trombose Venosa/induzido quimicamente , Antipsicóticos/uso terapêutico , Humanos , Loxapina/uso terapêutico , Masculino , Transtornos Psicóticos/tratamento farmacológico , Risperidona/uso terapêuticoRESUMO
No comparative trials versus well-established drugs; worrisome risk of bronchospasm; unsuitable mode of administration for agitated, often uncooperative patients.
Assuntos
Antipsicóticos/efeitos adversos , Loxapina/efeitos adversos , Administração por Inalação , Espasmo Brônquico/induzido quimicamente , Humanos , Loxapina/administração & dosagemRESUMO
Drug interaction is a frequent situation in pediatrics and child psychiatry. Carbamazepine (CBZ) is an antiepileptic drug used as a mood stabilizer in child psychiatry. CBZ is known to be a potent inducer of various CYP isoenzymes of cytochrome P450, which might result in a decrease in the plasma concentration of associated treatments. We describe two cases of CBZ overdosage in adolescent inpatients (14 and 16 years). The patients were treated with risperidone associated with fluoxetine in one and with loxapine in the other case, and CBZ was introduced as a mood stabilizer. Patients presented typical clinical symptoms (fatigue, dizziness, gastrointestinal signs, blurred vision). Overdosage was confirmed by an elevated CBZ plasma concentration (17 and 15.5 mg/L, therapeutic range 4-12 mg/L). We recommend introducing CBZ very progressively in patients treated with psychotropics, particularly when it is associated to several treatments. An intensification of clinical and biological follow-up with early plasma concentration testing should allow for better treatment adjustment.